Welcome to our dedicated page for Bionoid Pharma news (Ticker: BINP), a resource for investors and traders seeking the latest updates and insights on Bionoid Pharma stock.
Stay informed about AI Maverick Intel's developments in artificial intelligence technology, business acquisitions, and platform enhancements. The company's news flow typically covers updates to its AI Maverick platform, strategic partnerships, e-commerce expansions, and corporate developments related to its growth strategy.
Key news categories include platform feature releases and technological enhancements to the AI Maverick system, which continuously evolves to incorporate new machine learning capabilities and automation features. Announcements in this category detail improvements to contact intelligence, communication personalization, and autonomous sales dialogue capabilities.
Acquisition and partnership announcements represent significant news events, as the company actively pursues businesses that can benefit from AI-enhanced customer acquisition. These transactions typically involve e-commerce platforms, healthcare-related businesses, or companies in sectors where the AI Maverick technology can drive meaningful performance improvements. News in this category often includes details about revenue retention arrangements, integration timelines, and strategic rationale.
Corporate governance news covers regulatory filings, marketplace uplisting applications, and structural changes to the company's operations. As an OTC-traded entity pursuing OTCQB status, the company releases updates regarding its compliance efforts, disclosure practices, and steps taken to enhance shareholder value and market access.
Revenue and performance updates provide insights into how the company's dual business model performs, including both platform licensing results and outcomes from acquired business operations. These announcements help investors understand the effectiveness of the company's AI technology in real-world applications and the success of its acquisition integration efforts.
Industry trend analysis and market commentary may appear in company communications, particularly regarding developments in AI technology, customer acquisition methodologies, and digital transformation initiatives across target sectors. Such content positions the company within broader technology and business trends while demonstrating thought leadership in AI-powered sales automation.
AI Maverick Intel (OTCID:BINP) announced significant corporate developments following its transformation from Bionoid Pharma Inc. The company has launched its next-generation AI prospecting engine in July 2025, designed to automate sales development processes without human intervention.
The platform features comprehensive contact intelligence and context-aware communication capabilities, handling both transactional and consultative sales. Operating in a market projected to grow from $20.44 billion in 2024 to $82.23 billion by 2030, the company's solution can be deployed in under one business day. The platform targets high-value verticals including healthcare, biotech, insurance, and transportation sectors.
AI Maverick Intel (OTC:BINP) has partnered with IBN to enhance its corporate communications strategy. The company, which recently rebranded and acquired the AI Maverick platform in May 2025, specializes in AI-powered customer acquisition and engagement solutions.
The company's enhanced platform, launched in July 2025, features dynamic contact intelligence and autonomous dialogue capabilities for sales automation. The platform can be implemented within 24 hours and operates in sectors including healthcare, biotech, insurance, and transportation. AI Maverick Intel is positioned to capitalize on the AI-in-marketing sector's projected growth to $82.23 billion by 2030.
IBN, with its network of over 5,000 syndication outlets and 19-year track record serving 500+ clients, will provide comprehensive investor communications and market awareness services for BINP.
AI Maverick Intel (OTCID: BINP) has launched its enhanced prospecting platform designed to automate sales processes without requiring additional SDR teams. The next-generation engine features comprehensive contact intelligence and context-aware communication capabilities, leveraging millions of data points to create unified prospect profiles.
The platform now handles both transactional and consultative sales processes, managing discovery questions, objections, and scheduling. CEO Wayne Cockburn emphasizes the platform's ability to replicate human-quality conversations at scale, particularly beneficial in industries like insurance and transportation where meaningful interactions are crucial for sales success.
Bionoid Pharma (OTC:BINP) has received approval from Delaware for its name change to AI Maverick Intel, effective April 30, 2025. The company has initiated the FINRA process to update its name and trading symbol on OTC Markets. This rebranding reflects the company's strategic pivot towards leveraging artificial intelligence for acquiring and growing technology-driven businesses, particularly in AI, biotech, and digital health sectors.
Bionoid Pharma Inc. (OTC PINK:BINP) has announced its corporate rebranding to AI Maverick Intel, Inc., marking a strategic pivot towards AI-driven innovation. The rebranding follows the company's acquisition of AI Maverick Intel, a platform specializing in AI solutions for automated audience engagement.
The company's flagship AI Maverick platform focuses on streamlining customer acquisition processes through intelligent, two-way communication and data-driven interactions across healthcare, biotech, and other sectors. CEO Wayne Cockburn emphasized that this transformation represents their commitment to pioneering AI technologies for meaningful engagement and sustainable growth.
Bionoid Pharma (OTC PINK:BINP) has announced the completion of its audited financial statements for fiscal year 2024. The audit was performed by Aloba Awomolo & Partners LLP, Chartered Professional Accountants. CEO Wayne Cockburn highlighted this as a significant milestone for the company, positioning them for their next phase of corporate growth strategy.
The company plans to use this audit completion as a stepping stone toward their application to uplist to a more senior stock exchange. The audited financial statements will be made available on the OTC Markets website, demonstrating the company's commitment to transparency and corporate governance.
Bionoid Pharma (OTC PINK:BINP) has appointed Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year 2024. This strategic move follows the company's recent application to uplist to the OTCQB Venture Market.
The engagement of the new auditor demonstrates Bionoid's focus on enhancing financial governance and transparency, aimed at providing investors with improved visibility and liquidity. The audit is positioned as a important step in the company's strategy to achieve a more senior market listing.
Bionoid Pharma (OTC PINK:BINP) has submitted an application to uplist from OTC Pink to the OTCQB Venture Market. The process involves OTC Markets Group reviewing the company's financials, governance, and disclosures.
Upon approval, Bionoid will be able to utilize the SEC's modernized Rule 15c2-11 framework, enabling enhanced market maker participation through the IDQS system without the traditional 30-day waiting period. CEO Wayne Cockburn stated this move aims to enhance trading efficiency, liquidity, and price discovery, benefiting both institutional and retail investors.
The uplisting remains subject to final approval, with the company committed to providing updates throughout the process.
Bionoid Pharma (OTC PINK:BINP) has announced the completion of its financial audits for fiscal years 2022 and 2023 by PCAOB-registered firm Olayinka Oyebola & Co. This development represents a key milestone in the company's commitment to financial transparency and regulatory compliance.
The audits were conducted according to Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy of Bionoid's financial reporting. The firm is also on schedule to complete the company's 2024 financial statements.
CEO Wayne Cockburn emphasized that this achievement aligns with Bionoid's expansion strategy, which focuses on strategic acquisitions and AI-driven growth initiatives. The company is particularly targeting revenue-generating e-commerce acquisitions and continues to integrate its AI Maverick platform for sustainable growth.
Bionoid Pharma (OTC PINK:BINP) has outlined its corporate growth strategy for 2025, focusing on two main pillars: acquiring revenue-positive e-commerce websites in the health and wellness sector and implementing its proprietary AI Maverick Intel platform. The AI-driven marketing system aims to enhance customer engagement, optimize advertising efficiency, and deliver tailored user experiences.
CEO Wayne Cockburn emphasized the company's vision of scaling operations through strategic acquisitions while leveraging AI technology. The company plans to expand its portfolio with high-value, revenue-generating e-commerce websites in the health and wellness sector, with each acquisition aligned to support long-term objectives.
FAQ
What is the current stock price of Bionoid Pharma (BINP)?
What is the market cap of Bionoid Pharma (BINP)?
